Clinical Trial Update: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on peritransplant ruxolitinib for patients with primary or secondary myelofibrosis, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING